Alimentary Pharmacology & Therapeutics · 2019 · 92 citations · 30 references
Veterinary MedicineHealth PromotionExercise PrescriptionInflammationPhysical ActivityBiomarkers Of Liver InjuryHepatic PathophysiologyIndividualized Exercise ProgrammingLiver DiseaseMetabolic Adaptation To ExerciseMetabolic Liver DiseaseAssigned Goal SettingExercise ObjectivesExercise ParticipantsHepatic Fibrosis BiomarkersHepatic Steatosis AssessmentLiver Fibrosis BiomarkersSteatosis BiomarkersSteatosis Quantification
BACKGROUND: Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS: To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS: Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback. RESULTS: by 12.2% compared to baseline (P < .001). ALT and AST decreased by 14.3% (P = .002) and 18.2% (P < .001) and remained at this level until follow-up 12 weeks after the intervention. Markers of inflammation including hsCRP, ferritin, and M30 decreased. In parallel, gut microbiota exhibited increased metagenomic richness (P < .05) and at the taxonomic levels Bacteroidetes and Euryarchaeota increased whereas Actinobacteria phylum decreased. Surrogate scores of steatosis and fibrosis including the fatty liver index (FLI), FiB-4, APRI and transient elastography showed significant reductions. In parallel, a marker of procollagen-3 turnover (PRO-C3) decreased while C4M2, reflecting type IV collagen, degradation increased suggesting beneficial hepatic fibrosis remodelling from exercise. Also, an enhancement in health-related quality of life was reported. CONCLUSION: The current study underlines the plausibility and potential of an 8 week individualised web-based exercise program in NAFLD. Clinical trial number: NCT02526732.
30
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
Carol Ewing Garber, Bryan Blissmer, Michael R. Deschenes et al. · Medicine & Science in Sports & Exercise · 2011 · 9.1K citations · Full text